Analyzing Medpace (NASDAQ:MEDP) and NewGenIvf Group (NASDAQ:NIVF)

Medpace (NASDAQ:MEDP) and NewGenIvf Group (NASDAQ:NIVF) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Insider and Institutional Ownership

78.0% of Medpace shares are owned by institutional investors. Comparatively, 66.2% of NewGenIvf Group shares are owned by institutional investors. 20.3% of Medpace shares are owned by insiders. Comparatively, 31.8% of NewGenIvf Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Medpace and NewGenIvf Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	2	8	4	0	2.14
NewGenIvf Group	1	0	0	0	1.00

Medpace currently has a consensus price target of $483.45, indicating a potential upside of 7.02%. Given Medpace’s stronger consensus rating and higher possible upside, research analysts clearly believe Medpace is more favorable than NewGenIvf Group.

Profitability

This table compares Medpace and NewGenIvf Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medpace	17.83%	118.82%	25.07%
NewGenIvf Group	N/A	N/A	N/A

Earnings and Valuation

This table compares Medpace and NewGenIvf Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53 billion	5.07	$451.12 million	$15.30	29.53
NewGenIvf Group	$5.43 million	0.15	-$520,000.00	N/A	N/A

Medpace has higher revenue and earnings than NewGenIvf Group.

Risk and Volatility

Medpace has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Comparatively, NewGenIvf Group has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500.

Summary

Medpace beats NewGenIvf Group on 11 of the 12 factors compared between the two stocks.

About Medpace

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

About NewGenIvf Group

NewGenIVF Group Ltd. operates as an assisted reproductive services provider. It focuses on providing fertility treatments to fulfil the dreams of building families. The firm offers in-vitro fertilization treatment service, comprising traditional IVF and egg donation, and surrogacy and ancillary caring services. The company was founded by Siu Wing Fung and Fong Hei Yue on January 16, 2019 and is headquartered in Bangkok, Thailand.